Thymoquinone-loaded lipid nanocapsules with promising anticancer activity for colorectal cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nanoscale Advances Année : 2023

Thymoquinone-loaded lipid nanocapsules with promising anticancer activity for colorectal cancer

Résumé

Colorectal cancer (CRC) is the third most common worldwide. Depending on its stage, chemotherapy is usually given after surgery when CRC has already metastasized to other organs like the liver or lungs. Unfortunately, the current antineoplastics used for CRC therapies involve toxicity and side effects due to their lack of site-specificity. To overcome the drawbacks of heavy chemotherapy, this study proposes to assess the efficacy of thymoquinone (TQ), a bioactive constituent of black seeds (Nigella sativa), as an antiproliferative and pro-apoptotic agent on an experimental CRC model in mice. TQ was encapsulated in lipid nanocapsules (LNCs), used as nanocarriers, in order to increase its specificity and cell absorption. TQ-loaded LNCs (TQ-LNCs) have a diameter of 58.3 ± 3.7 nm and 87.7 ± 4.5% TQ encapsulation efficiency. In turn, in vivo studies showed that the intratumoral administration of TQ-LNCs decreased the tumor size in colorectal cancer bearing mice compared to the control group. TQ-LNCs were more effective than free TQ for inducing tumor cell death. These results highlight the potential of TQ entrapped in LNCs as an anticancer agent for CRC treatment.
Fichier principal
Vignette du fichier
Selmi et al 2023.pdf (3.24 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04210022 , version 1 (18-09-2023)

Identifiants

Citer

Mouna Selmi, Abir Salek, Mahassen Barboura, Leila Njim, Amine Trabelsi, et al.. Thymoquinone-loaded lipid nanocapsules with promising anticancer activity for colorectal cancer. Nanoscale Advances, 2023, ⟨10.1039/d3na00445g⟩. ⟨hal-04210022⟩
8 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More